期刊文献+

含吡啶-2-酰肼结构的索拉非尼类似物的设计、合成及其抗肿瘤活性 被引量:5

Design,synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety
原文传递
导出
摘要 本文通过对已上市靶向抗肿瘤药sorafenib进行结构改造,设计合成了一系列含吡啶-2-酰肼结构的sorafenib类似物,并采用MTT法,评价了其对5种肿瘤细胞株的生长抑制作用。结果表明,大多数化合物具有一定的抑制肿瘤细胞增殖的活性,其中化合物2c、2d和2f抑制胰腺癌Mia-PaCa-2、SW1990细胞生长的作用强于阳性对照sorafenib,化合物3f和3g对于肝癌细胞株HepG2的抑制活性是sorafenib的2~3倍,明显优于阳性对照。 A novel series of sorafenib analogs containing 2-picolinyl hydrazide moiety were designed and synthesized. In vitro, most of synthesized compounds have antiproliferation activity on MDA-MB-231, ACHN, HepG2, Mia-PaCa-2 and SW1990 cell lines tested by MTT assay. It is worth noting that the antitumor activities of compounds 2c, 2d and 2f are more potent than that of sorafenib on pancreatic cancer cells Mia-PaCa-2 and SW1990, and the activities of compounds 3f and 3g are 2-3 times than that of sorafenib on human hepatocellular carcinoma HepG2 cell line.
出处 《药学学报》 CAS CSCD 北大核心 2012年第12期1623-1629,共7页 Acta Pharmaceutica Sinica
基金 "十二五重大新药创制"科技重大专项资助项目(2012ZX09103-101-019)
关键词 吡啶-2-酰肼结构 索拉非尼 抗肿瘤 构效关系 2-picolinylhydrazide sorafenib antitumor structure-activity relationship
  • 相关文献

参考文献2

二级参考文献47

  • 1Hui-Zhong Zhang Jin-Geng Liu Yi-Ping Wei Cheng Wu Yong-Ke Cao Mei Wang.Expression of G3BP and RhoC in esophageal squamous carcinoma and their effect on prognosis[J].World Journal of Gastroenterology,2007,13(30):4126-4130. 被引量:12
  • 2Tang ZY. Modem Oncology(现代肿瘤学)[M].2nd ed. Shanghai: Fudan University Press, 2003:202 - 223.
  • 3Huang WL, Zhu XF. Signal Transduction (信号转导)[M]. Beijing: People's Medical Publishing House, 2005:151 - 199.
  • 4Seboh-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules [ J ]. Nature, 2006, 441:457 -462.
  • 5Liebmann C. Regulation of MAP kinase activity by peptide receptor signalling pathway : paradigms of multiplicity [ J]. Cell Signal, 2001,13:777 - 785.
  • 6Shaw RJ, Cantley LC. Ras, PI (3)K and mTOR signaling controls tumour cell growth [ J ]. Nature, 2006, 441:424 - 430.
  • 7Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage [ J]. Clin Cancer Res, 2006, 12 : 1398 - 1401.
  • 8Schenone S, Manetti F, Botta M. Src inhibitors and angiogenesis [ J ]. Curr Pharm Design, 2007,13:2118 - 2128.
  • 9Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia [J]. Nat Rev Cancer, 2007,7:345 -356.
  • 10Murray PJ. The JAK-STAT signaling pathway: input and output integration [ J ]. J Immunol, 2007,178 : 2623 - 2629.

共引文献56

同被引文献52

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部